ProQR Therapeutics BV

PRQR

ProQR Therapeutics NV (NASDAQ: PRQR) is a Dutch biotechnology company based in Leiden, the Netherlands. ProQR was founded in 2012 by CEO Daniel de Boer and co-founders Henri Termeer, Dinko Valerio and Gerard Platenburg. The company’s current pipeline includes potential treatments for rare genetic diseases including Leber's congenital amaurosis, (LCA10) dystrophic epidermolysis bullosa and Usher syndrome.ProQR is targeting genetic diseases by focusing on making changes to the RNA. The firm's RNA editing technology, called Axiomer, can make targeted single nucleotide changes to RNA. One of the company’s lead candidates, QR-110, is being developed to treat LCA10. The substance acts by binding the mutated section of the RNA which will allow a formation of a normal CEP290 protein.

ProQR Therapeutics BV has been a target of short sellers for a while. The current short interest of 2.34% is roughly at the average of the last 12 months (1.38%).